Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
Crossref DOI link: https://doi.org/10.1186/s41181-016-0014-4
Published Online: 2016-05-14
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chan, Ho Sze
de Blois, Erik
Konijnenberg, Mark W.
Morgenstern, Alfred
Bruchertseifer, Frank
Norenberg, Jeffrey P.
Verzijlbergen, Fred J.
de Jong, Marion
Breeman, Wouter A. P.
License valid from 2016-05-14